Nice | Rivaroxaban in Acute Coronary Syndrome (ACS)

27th May 2015 by Louise Hudman

Nice | Rivaroxaban in Acute Coronary Syndrome (ACS)

This new guideline from Nice states that rivaroxaban can now be used after ACS with elevated cardiac enzymes. It should be used either with aspirin, or with aspirin and clopidogrel together.

  • It decreases the combined end points of MI, CVA or deaths from cardiovascular events by 20%.
  • There is a 3 x increased risk of major bleeding, so bleeding risk must be assessed.
  • Use beyond 12m hasn’t been studied, so use beyond that point is for clinical judgement.

It is generally started about a week after the event, so it is likely that we will be starting it, though hopefully it will be advised in the discharge summary.

Join

Join to view the rest of this content, as well as access all the benefits of joining NASGP.

Join

Login

Already a member? Login to view this content.

Login

"A must-have for any GP locum.

I have used NASGP website since I started locuming three years ago. It caters for all my locum needs, and I found LocumDeck particularly useful for bookings and invoicing. The automatically-generated invoices and pension forms save me countless hours of admin time every month, and the recently introduced e-signed forms are brilliant.

The assistance I have received has always been quick and helpful. The forums and updates have also kept me in the loop with important issues which may affect my practice.

I cannot recommend this website enough. "

Dr Suzanne Gaskell

Dr Suzanne Gaskell

See the full list of features within our NASGP membership plans

Membership